Omnix Medical Advances OMN6 into Phase II Trial for Drug-Resistant Acinetobacter Infections

Omnix Medical Reaches an Important Clinical Milestone

Omnix Medical has announced an important step forward in the development of its lead drug candidate, OMN6. The company has successfully dosed the first patients in its ongoing Phase II clinical trial, which is evaluating the treatment in severe multidrug-resistant Acinetobacter baumannii infections.

The first patients were enrolled and treated at leading medical centers in Israel, including Rabin Medical Center (Beilinson Hospital), Samson Assuta Ashdod University Hospital, and Shamir Medical Center.

This milestone brings OMN6 closer to demonstrating its potential as a new treatment option for patients facing life-threatening infections with very limited therapeutic choices.

Why Acinetobacter baumannii Is a Major Global Health Concern

If you work in healthcare or follow developments in infectious diseases, you have probably heard about Acinetobacter baumannii.

This Gram-negative bacterium is one of the most dangerous hospital-acquired pathogens worldwide. It is particularly common in intensive care units, where it can cause severe infections such as hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

The situation becomes even more serious when the bacteria develop resistance to carbapenems, which are often considered last-line antibiotics. These carbapenem-resistant Acinetobacter baumannii (CRAB) infections are extremely difficult to treat and can lead to very high mortality rates.

According to clinical experts, mortality rates among critically ill patients infected with carbapenem-resistant strains can reach as high as 60%.

Because of the growing threat posed by these infections, the World Health Organization (WHO) has classified Acinetobacter baumannii as a critical priority pathogen requiring urgent development of new treatment options.

Understanding the Phase II Clinical Trial

The ongoing Phase IIa study is designed to evaluate the safety, tolerability, and pharmacokinetic profile of OMN6 in patients with severe bacterial pneumonia caused by Acinetobacter baumannii complex.

The trial is a:

• Prospective study

• Multinational study

• Multicenter study

• Randomized study

• Double-blind study

• Placebo-controlled study

• Dose-ranging study

Researchers are evaluating OMN6 in patients suffering from hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, including infections caused by carbapenem-resistant strains.

The primary goal is to identify safe and well-tolerated dose levels while gathering important clinical data on how the drug behaves in patients.

What Makes OMN6 Different?

One of the biggest challenges in treating multidrug-resistant infections is that many existing antibiotics work through mechanisms that bacteria have already learned to resist.

OMN6 was developed with a different approach.

The investigational therapy is a first-in-class antimicrobial peptide designed to physically disrupt bacterial membranes. Instead of interfering with bacterial growth pathways, OMN6 directly attacks the outer membrane of the pathogen.

The treatment selectively binds to bacterial membranes and rapidly destabilizes them, causing bacterial cell death.

This membrane-disrupting mechanism offers two potential advantages:

• Rapid bacterial killing

• Reduced likelihood of resistance development

Because the drug works differently from traditional antibiotics, researchers believe it may provide an important new option for difficult-to-treat infections.

A Novel Antimicrobial Peptide Derived from Nature

OMN6 belongs to a class of therapies known as antimicrobial peptides (AMPs).

These naturally inspired compounds are part of the immune defense systems found in many living organisms. OMN6 itself is derived from naturally occurring antimicrobial peptides originally found in insects.

Scientists have engineered the compound to specifically target multidrug-resistant Gram-negative pathogens while maintaining a favorable safety profile.

The result is a fast-acting therapy designed to address one of the most urgent challenges in modern infectious disease treatment.

Experts Highlight the Need for New Treatment Options

Medical experts involved with the program have emphasized the urgent need for innovative anti-infective therapies.

Professor Keith Kaye, Chief of the Division of Allergy, Immunology and Infectious Diseases at Rutgers Robert Wood Johnson Medical School and a member of Omnix Medical's Clinical Advisory Board, noted that treatment options remain extremely limited for patients suffering from carbapenem-resistant Acinetobacter baumannii infections.

He highlighted the growing global spread of multidrug-resistant Gram-negative pathogens and the need for new therapeutic approaches with differentiated mechanisms of action.

Professor Yehuda Carmeli, Head of the National Institute for Antibiotic Resistance and Infection Control at Tel Aviv Medical Center and a member of Omnix Medical's Clinical Advisory Board, also emphasized the potential value of OMN6's membrane-disrupting mechanism.

According to Professor Carmeli, innovative antimicrobial peptides may offer an important new strategy in situations where resistance continues to rise and available treatment options remain inadequate.

Company Leadership Sees Strong Potential

Dr. Moshik Cohen-Kutner, Co-Founder and Chief Executive Officer of Omnix Medical, described the dosing of the first patient as a major milestone for the company.

He explained that OMN6 was specifically engineered to target bacterial membranes and rapidly destroy harmful pathogens while minimizing the potential for resistance development.

The company believes this differentiated mechanism could help address a significant unmet medical need among patients with severe multidrug-resistant Gram-negative infections.

The ongoing Phase II study will play an important role in determining whether OMN6 can deliver the expected clinical benefits in real-world patient settings.

Building on Successful Phase I Development

Before entering Phase II testing, OMN6 successfully completed Phase I clinical development.

The current study represents the next step in evaluating the treatment's safety and effectiveness in patients suffering from active infections.

If successful, the program could move closer to larger late-stage clinical studies and eventually provide a new treatment option for healthcare providers dealing with highly resistant bacterial infections.

Omnix Medical's Mission to Fight Antibiotic Resistance

Founded in 2015, Omnix Medical was established with a clear mission: address the growing global crisis of antibiotic-resistant bacterial infections.

Since its founding, the company has received support from several major organizations, including:

• The Israeli Innovation Authority

• The European Union through the EIC Accelerator and Horizon 2020 programs

• The U.S. National Institutes of Health (NIH)

These collaborations have helped advance the development of OMN6 and support the company's broader efforts to create next-generation anti-infective therapies.

Looking Ahead

The start of patient dosing in the Phase II trial marks an important moment for Omnix Medical and for the fight against multidrug-resistant infections.

With Acinetobacter baumannii continuing to pose a serious threat in hospitals around the world, the need for innovative treatments has never been greater.

OMN6's unique membrane-disrupting mechanism, promising preclinical and early clinical results, and focus on one of the world's most dangerous bacterial pathogens position it as a potentially important addition to the future anti-infective treatment landscape.

As the Phase II trial progresses, researchers, clinicians, and healthcare systems will be watching closely to see whether OMN6 can deliver a meaningful new solution for patients facing life-threatening drug-resistant infections.

About Omnix Medical

Omnix Medical is a biopharmaceutical company focused on developing next-generation anti-infective therapies for severe multidrug-resistant bacterial infections. Founded in 2015, the company is advancing innovative antimicrobial peptide technologies designed to address urgent unmet medical needs in infectious disease treatment.

Its lead candidate, OMN6, is currently being evaluated in clinical studies for the treatment of multidrug-resistant Acinetobacter baumannii infections and other serious Gram-negative bacterial diseases.